معرفی
Axel Hyrenius Wittsten is an active Researcher at Lund University's Division of Clinical Genetics and Lund University Cancer Centre (LUCC), with additional responsibilities as Manager of Synthetic Immunology. His work focuses on the pathogenetic mechanisms behind MLL-rearranged acute leukemia in infancy and translational genomic and functional studies of leukemia.
Dr. Wittsten's research interests span leukemia genomics, chromatin accessibility in KMT2A-rearranged acute leukemia, CAR T-cell therapy mechanisms, and synthetic immunology approaches for cancer treatment. His work contributes significantly to UN Sustainable Development Goals related to health and well-being.
His recent publications demonstrate expertise in single-cell genomics of B-cell precursor acute lymphoblastic leukemia, chromatin remodeling in KMT2A-rearranged leukemia, CAR T-cell exhaustion mechanisms in multiple myeloma, and innovative synthetic receptor designs for cell-based therapies. These works collectively advance understanding of leukemia pathogenesis and immunotherapy development.
Dr. Wittsten currently leads two major research projects: 'Enhancing the specificity of cell-based immunotherapy for acute myeloid leukemia' (2023-2027) funded by The Swedish Childhood Cancer Fund, Crafoord Foundation, and Mats Paulssons stiftelse; and 'Boosting the therapeutic potential of engineered T cells through revamped synthetic circuits' (2022-2026) funded by the Swedish Research Council and Cancerfonden.
He is an active participant in the cancer research community, frequently presenting at and organizing events including LUCC seminars on cell-based therapies, Lund University Cancer Centre meetings, and World Cancer Day activities. His collaborative network spans multiple institutions and countries, reflecting the international nature of his research.
